The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Regeneron Pharmaceuticals competitive analysis

Loading summary...

Latest oppositions filed by Regeneron Pharmaceuticals

Explore patent oppositions filed by Regeneron Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3411476
Enhanced Production Of ImmunoglobulinsTRIANNIJan 24, 2025
EP3819007
Dosing Regimen For Anti-Bcma AgentsAMGENAug 2, 2024
EP4058148
Dosing Regimen For Anti-Bcma AgentsAMGENAug 2, 2024
EP3631454
Treatment Of Lag-3 Positive TumorsBRISTOL MYERS SQUIBBJun 13, 2024
EP3911354
Aav-Mediated Gene Therapy Restoring The Otoferlin GeneCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSApr 16, 2024
EP3666797
Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)AMGENFeb 19, 2024
EP3597216
Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses ThereofE R SQUIBB & SONSMay 23, 2023
EP3476942
Long Germline Dh Genes And Long Hcdr3 AntibodiesTRIANNIOct 25, 2022
EP3785536
Adam6 Knockin MiceTRIANNIOct 25, 2022
EP3241435
Animal Models And Therapeutic MoleculesKYMABFeb 25, 2022

Latest patents of Regeneron Pharmaceuticals opposed by its competitors

Explore Regeneron Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP4252857
Sep 25, 2024Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)1
EP3506931
Jul 31, 2024Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist4
EP3889181
Apr 24, 2024Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist7
EP3460063
Mar 13, 2024Methods And Compositions For The Targeted Modification Of A Genome1
EP3110848
Feb 14, 2024Methods For Treating Skin Infection By Administering An Il-4R Antagonist5
EP3515465
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R Inhibitor7
EP3973987
Jan 10, 2024Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist7
EP4011915
Nov 15, 2023Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist6
EP3703818
Nov 1, 2023Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist7
EP2967015
Aug 9, 2023Transgenic Mice Expressing Chimeric Major Histocompatibility Complex (Mhc) Class Ii Molecules1

Latest PTAB cases involving Regeneron Pharmaceuticals

Discover the latest PTAB cases involving Regeneron Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 16, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Regeneron Pharmaceuticals

PGR2025-00085Sep 17, 2025ALVOTECH USAREGENERON PHARMACEUTICALSPending
IPR2025-01268Jul 14, 2025FRESENIUS KABI SWISSBIOSIMREGENERON PHARMACEUTICALSPending
IPR2025-01269Jul 14, 2025FRESENIUS KABI SWISSBIOSIMREGENERON PHARMACEUTICALSPending
IPR2025-00456Jan 15, 2025CELLTRIONREGENERON PHARMACEUTICALSDiscretionary Denial
IPR2025-00233Dec 2, 2024FORMYCONREGENERON PHARMACEUTICALSInstitution Denied
IPR2025-00176Nov 20, 2024SAMSUNG BIOEPISREGENERON PHARMACEUTICALSInstitution Denied
IPR2024-00298Dec 18, 2023BIOCON BIOLOGICSREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2024-00260Dec 14, 2023CELLTRIONREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2024-00201Nov 20, 2023BIOCON BIOLOGICSREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2023-01312Aug 18, 2023SAMSUNG BIOEPISREGENERON PHARMACEUTICALSTerminated-Adverse Judgment

Peer Comparison New

IP litigation analysis comparing Regeneron Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
REGENERON PHARMACEUTICALS3894931
AMGEN8138811
BOULT WADE TENNANT53 - - -
KYMAB814 - 5